The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 9, 2023. Its latest SEC filing is a 15-12G from Oct 10, 2023.
10-Q for Q2 FY2023, filed Aug 9, 2023
The sections below describe the company as of the FY2022 annual report.
Provides clinical-development services to biopharmaceutical companies, biotechnology firms, and medical-device makers, as well as commercialization services.
10-K for FY2022, filed Feb 16, 2023Our operations are divided into two reportable segments, Clinical Solutions and Commercial Solutions. Our Clinical Solutions segment offers…View ↗
Our Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public…View ↗
Our full-service clinical development offering provides comprehensive solutions to address the clinical development needs of our customers…View ↗
Customers pay for clinical-development and commercialization services over the period the work is carried out; longer clinical projects span several years, while many other service arrangements are short-term or month-to-month.
10-K for FY2022, filed Feb 16, 2023The majority of the Company’s revenue arrangements are service contracts that range in duration from a few months to several years.…View ↗
The Company’s Clinical Solutions segment provides solutions to address the clinical development needs of customers. The Company provides…View ↗
The remaining service offerings within the Clinical Solutions segment are generally short-term, month-to-month contracts, time and…View ↗
The remaining Commercial Solutions contracts are generally short-term, month-to-month contracts or time and materials contracts. As such…View ↗
10-K for FY2022, filed Feb 16, 2023
FY2022 revenue by reportable segment ↗$5.4B
10-K for FY2022, filed Feb 15, 2023
$5.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Clinical Solutions
Recurring
10-K for FY2022, filed Feb 16, 2023 |
75%
FY2019: 74%
|
Clinical Solutions, FY2022
$4.1B Sources
|
Recurring |
|
Commercial Solutions
Recurring
10-K for FY2022, filed Feb 16, 2023 |
25%
FY2019: 26%
|
Commercial Solutions, FY2022
$1.3B Sources
|
Recurring |
Serves large biopharmaceutical companies, emerging and specialty biotechnology firms, and medical-device and diagnostics companies. Its business-development staff identifies needs and designs solutions, while account teams manage key customer relationships.
10-K for FY2022, filed Feb 16, 2023We have a well-diversified customer base of over 900 customers, which includes many of the world’s largest biopharmaceutical companies…View ↗
Our global team of strategic business development professionals and support staff identifies needs, designs solutions, and promotes our…View ↗
Our business development organization works with our leadership team to identify, develop, and maintain key customer relationships in…View ↗
Yes. It kept 5 cents of every revenue dollar as net income in FY2022 and turned 6 cents into free cash flow.
10-K for FY2022, filed Feb 15, 2023
$403.2MView ↗
10-K for FY2022, filed Feb 15, 2023
$266.5MView ↗
10-K for FY2022, filed Feb 15, 2023
$333.5MView ↗
10-Q for Q2 FY2023, filed Aug 9, 2023
Open tableView ↗
8-K, filed Oct 3, 2023
On October 3, 2023, Syneos Health, Inc. (the “Company”) publicly announced that Colin Shannon has been appointed Chief Executive Officer of…View ↗
8-K, filed Sep 28, 2023
On September 28, 2023, in connection with the consummation of the Merger, the Company repaid in full all outstanding loans, together with…View ↗
Grew. Revenue grew 23% in 4 years, from $4.4B in FY2018 to $5.4B in FY2022, about 5% a year.
Loading...
